89 results
Page 3 of 5
8-K
EX-99.1
b9cf8b2ey01
19 Apr 21
OVID Provides Update on OV101 Program and the Prioritization of its Resources
8:31am
8-K
EX-99.1
adj5ndzyhf4idwwui
9 Apr 21
Regulation FD Disclosure
10:01am
8-K
EX-99.1
0gb1hsyf
30 Mar 21
Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat
8:05am
8-K
EX-99.1
62fwfv1i9yx
15 Mar 21
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
8:05am
8-K
EX-99.1
0sbahhfak3927yr6d3
3 Mar 21
Regulation FD Disclosure
10:05am
424B5
jk8bx3eq 81ftn
20 Nov 20
Prospectus supplement for primary offering
4:23pm
8-K
EX-99.1
xew9pphlod8 q5
22 Oct 20
Regulation FD Disclosure
1:14pm
424B5
96dqhf4
26 Aug 20
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
pan03jwbjtjz9npz
10 Aug 20
Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
8:06am
424B5
6v7onz
12 Nov 19
Prospectus supplement for primary offering
8:02am